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Editorial 
Immunotherapy: a new strategy for tuberculosis 
control? 
It is an undisputed fact that modern short-course 
chemotherapy can cure over 95% of patients with 
tuberculosis, providing that the bacilli are sus- 
ceptible to the drugs and that the patient com- 
plies fully with the prescribed course of treatment 
(1). Indeed, more research has been put into 
developing optimum drug regimens for tubercu- 
losis than for any other infectious disease. 
Why, therefore, did the World Health 
Organization (WHO) in 1993, two decades after 
the introduction of modern short-course chemo- 
therapy, take the unprecedented step of declaring 
tuberculosis a ‘global emergency’? The statistics 
are, by now, depressingly familiar: one-third of 
the world’s population infected, 10 million new 
cases of active tuberculosis and three million 
deaths annually, and a predicted 30-40 million 
needless deaths by the year 2004 unless we com- 
pletely revise our control strategies (2). To this 
tragic scenario, the impact of the HIV pandemic 
may be added. Indeed, so serious is this impact 
that any data on prevalence are outdated by the 
time they are published. As if all this is not bad 
enough, a combination of poor drug supply, 
sub-optimal formulations, faulty prescribing, in- 
terrupted drug supplies, poor compliance and 
many other factors has led to the widespread 
emergence of drug and multi-drug resistance. 
The obvious conclusion is that tuberculosis 
control measures which are irreproachable on 
paper have, with a few exceptions, proved singu- 
larly unsuccessful in practice (3). Unfortunately, 
the few ‘showcase’ successes have received undue 
emphasis in the literature. Also, despite the 
thoroughly researched statement of the WHO 
that, in terms of years of good quality human life 
saved, treatment of tuberculosis is among the 
most cost-effective of ail therapeutic inter- 
ventions, the extent of global financial aid allo- 
cated to control of this disease is derisory (2). 
One of the problems is the extraordinary stigma 
attached to tuberculosis. As early as 1908, 
Leonard Williams complained of the backsliding 
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and complacency of the medical profession (4) 
and the subsequent introduction of anti- 
tuberculosis drugs and BCG were more effective 
in eradicating interest in this disease than in 
eradicating the disease itself (5). 
The human race needs to make an unequivo- 
cal decision very soon. Do we want to conquer 
tuberculosis or would we prefer the disease 
to continue needlessly destroying the health of 
millions and depriving many of their lives? 
Assuming that we have enough humanity to 
select the former option, we need to ask some 
very fundamental questions concerning our 
approach to the control of the disease. 
The three major control strategies that have 
been intensively researched since the discovery of 
the tubercle bacillus by Koch in 1882 are chemo- 
therapy, vaccination and immunotherapy. The 
great benefits of chemotherapy cannot be 
doubted but, as outlined above, its deployment 
has been faced with serious difficulties, and its 
future usefulness is threatened by multi-drug 
resistance. Few pharmaceutical companies have 
the incentive to search for new anti-tuberculosis 
drugs; those agents emerging in recent years, 
such as quinolones and macrolides, were devel- 
oped for other purposes. Even if a powerful new 
agent was to be found, it would soon lead to yet 
another form of drug resistance unless the entire 
strategy of drug use and control is radically 
revised. Vaccination with BCG has certainly 
saved the lives of many children who would 
otherwise have developed serious forms of pri- 
mary disease such as tuberculous meningitis. By 
contrast, the impact of vaccination on the infec- 
tious (post-primary) forms of tuberculosis has 
been minimal and BCG has therefore contrib- 
uted little to the overall conquest of the disease. 
Large sums of money are being invested in 
‘molecular biology’ with the hope of character- 
izing protective epitopes and producing novel, 
recombinant, vaccines. Clearly, it is to be hoped 
that this intensive and costly work will lead to 
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much more effective vaccines capable of prevent- 
ing post-primary as well as primary disease, 
rather than a mere re-invention of the wheel. It 
should be noted, however, that even if such a 
vaccine is produced, its evaluation in the human 
population will be fraught with very serious 
problems and will take considerable time. 
In view of the difficulties and drawbacks of the 
conventional measures, we need to seriously 
consider novel ones. In this issue of Respiratory 
Medicine, results of clinical trials of an innova- 
tive form of tuberculosis control, namely im- 
munotherapy with a heat-killed suspension of 
Mycobacterium vaccae, are presented in two 
papers (6,7). The concept of immunotherapy has 
not been universally accepted and the approach 
taken over the last decade by Stanford et al. has 
not been free from criticism, sometimes quite 
hostile. Thus, a recapitulation of the history of 
this immunotherapeutic approach, the difficul- 
ties encountered in its clinical evaluation and the 
support of the concept from recent advances in 
immunology is indicated. 
Despite the fact that tuberculosis is such a 
prevalent and widespread disease, the human 
immune response is usually very good. Only 5% 
of persons infected by the tubercle bacillus 
develop clinically evident primary disease within 
3 yr of infection, and only a further 5% develop 
post-primary disease due to endogenous re- 
activation or exogenous re-infection years or 
decades later. Thus, in the absence of an obvious 
immunosuppressive disorder such as HIV infec- 
tion, the tubercle bacillus is non-pathogenic in 
90% of those infected. This begs the obvious 
question as to the nature of the difference 
between this protected majority and the minority 
of persons who develop the disease. For decades 
it has been suspected that immune responses 
leading to protective immunity on the one hand 
and to tissue-destroying hypersensitivity and 
progression of disease on the other are quali- 
tatively different (8). In 1975, Lefford postulated 
that the two opposing responses might be due to 
different T-lymphocyte populations, or to a sin- 
gle population at different stages of maturation 
(9). Recently, this postulate has been confirmed 
by the finding that T-helper cells mature into two 
functional types, Thl and Th2, and that the 
cytokines produced by one type inhibit the other 
maturation pathway (1). As a result, an immune 
response tends to become ‘locked in’ to one or 
other pattern of response (11). In many cases, 
an infection elicits (fortunately!) a protective 
response, but if for some reason the host is 
locked in to an inappropriate response, the 
response itself contributes to tissue damage and 
progression of disease. There is now ample 
evidence that a Thl response is required for 
protection against tuberculosis, whereas a Th2 
(or mixed Thl and Th2) response leads to tissue 
damage resulting, for example, in extensive pul- 
monary cavitation (12-14). Once the disease 
process of tuberculosis is established, endocrine 
changes due, at least in part, to the effect of 
cytokines on the adrenal gland, further enhance 
Th2 maturation and progression of the disease 
(15). Accordingly, recent immunological findings 
indicate that a therapeutic measure able to 
switch from a Th2 to a Thl response would be of 
great benefit in tuberculosis. In this context, 
heat-killed M. vaccae has been shown to be a 
powerful Thl adjuvant (12). 
The story of M vaccae as an immuno- 
therapeutic agent began, however, before these 
fascinating immunological discoveries threw 
light on its mode of action. The story, in fact, 
stemmed from the observations that the protec- 
tive efficacy of BCG varied greatly from one 
region of the world to another. In one area of 
Uganda, it is particularly effective in protecting 
against both tuberculosis and leprosy (16). This 
indicates that whatever affords protection must 
be common to M. tuberculosis and hf. leprae, 
and antigenic analysis has shown that what is 
common to these bacilli is common to all myco- 
bacteria. This, in turn, led to the hypothesis that 
the determinant of protection in the Ugandan 
environment would be a free-living myco- 
bacterium which, if isolated, might be harnessed 
as a vaccine against leprosy. As a result of a long 
series of investigations, a strain of M vaccae 
capable of inducing skin test reactivity and other 
correlates of protective immunity in patients 
with leprosy and tuberculosis was discovered 
(17). After extensive safety studies, it was tenta- 
tively introduced as an immunotherapeutic agent 
against human tuberculosis in 1987, and the 
results led to guarded optimism (18). 
This was when many problems began. The 
community of tuberculosis workers had by then 
become so ‘locked in’ to the dogma that 
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cure of this disease could only be achieved by a 
very long course of several chemotherapeutic 
agents that the idea of stimulating the patient’s 
innate defence mechanisms by a single in- 
jection appeared preposterous and outrageous. 
Sadly, the enormous amount of work on im- 
munotherapy in the pre-chemotherapy era, 
including that by Koch, has been largely 
forgotten. 
The only way to prove efficacy of this new 
form of immunotherapy was to undertake exten- 
sive, well-controlled, clinical trails but these are 
very costly. Requests for funding for such trials 
failed because there was no evidence that the 
new therapy would work - a veritable ‘Catch 22’ 
situation! Consequently, Stanford et al. had little 
choice but to conduct a series of small studies, 
often under very difficult conditions, in a 
number of developing countries with the gener- 
ous support and co-operation of dedicated local 
workers (19). Although without exception these 
studies pointed to a beneficial effect, critics com- 
plained that, because the studies had not been 
conducted to the very rigorous so-called ‘good 
clinical practice’ requirements of clinical trials, 
the results were, at best, anecdotal. Fortunately, 
funding was eventually obtained by launching a 
small company on the London Stock Exchange 
and extensive, well-controlled and monitored 
clinical studies of a standard required by regu- 
latory authorities are underway in South Africa 
and London. Patient intake in the former study 
was completed early in 1996 and results are 
expected by early 1997. 
The requirements for such studies raise a 
further problem and a paradox. For ethical 
reasons, it is necessary to provide all patients 
enrolled into the trials with a supervised, WHO- 
approved course of therapy which, as stated 
above, is expected to cure well over 95% of 
drug-susceptible cases. Thus, though for good 
reasons, immunotherapy is being evaluated 
under conditions least likely to demonstrate a 
highly significant effect. One of the papers in this 
issue illustrates this problem; there was little 
difference in the cure rate between the test and 
control groups with drug-susceptible disease, as 
both responded so well to chemotherapy (6). 
Also, the immunotherapy was given 1 month 
after starting chemotherapy, which now appears 
not to be the optimal time, and the rapidity of 
clearance of bacilli from sputum in the test and 
control groups was not compared. Nevertheless, 
other indicators of recovery including resolution 
of pulmonary lesions point to a beneficial effect 
of immunotherapy. The second paper shows a 
greater effect of immunotherapy when given to 
‘difficult-to-treat’ patients (7). Even greater dif- 
ferences between patients and controls were 
observed in a study in Kano, Nigeria, where 
drug supply was very inadequate and there 
was the additional complicating factor of HIV 
infection (20). 
If all patients with tuberculosis were diag- 
nosed accurately before they had infected other 
people, if they had drug-susceptible disease and 
if they received a full curse of directly observed 
therapy, short-course (DOTS), tuberculosis 
could be conquered (1). But we live in a real 
world in which tuberculosis is an ever-growing 
nightmare. Immunotherapy is not a miracle 
cure; it has never been intended to be more than 
an adjunct to anti-tuberculosis drugs, although it 
may enable short-course chemotherapeutic regi- 
mens to become even shorter. It does, however, 
appear to offer promise in those all too common 
situations in which chemotherapy alone fails due 
to drug resistance, lack of suitable drugs and 
problems of non-compliance (21). If we are to 
conquer tuberculosis, we need a well-funded 
global campaign spearheaded by the WHO 
which will not only deploy the available control 
measures to their best effect, but will incorporate 
innovations, such as immunotherapy, as and 
when they arise. 
The WHO declaration of tuberculosis as a 
global emergency should have shaken health 
services and funding bodies out of complacency 
and backsliding, and freed them from dogmas 
established decades ago. If not, in the words of 
Louis Pasteur, the (tubercle) bacillus will have 
the last laugh. 
J. M. GRANGE 
National Heart and Lung Institute, 
Imperial College School of Medicine, 
London, U.K. 
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